Bank OZK Has $3.33 Million Stake in Amgen Inc. (NASDAQ:AMGN)

Bank OZK increased its holdings in Amgen Inc. (NASDAQ:AMGN) by 1.3% in the fourth quarter, Holdings Channel reports. The institutional investor owned 11,576 shares of the medical research company’s stock after buying an additional 145 shares during the period. Amgen makes up 1.6% of Bank OZK’s holdings, making the stock its 12th largest holding. Bank OZK’s holdings in Amgen were worth $3,334,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Fuller & Thaler Asset Management Inc. raised its position in Amgen by 1.7% during the third quarter. Fuller & Thaler Asset Management Inc. now owns 11,658 shares of the medical research company’s stock valued at $3,133,000 after purchasing an additional 193 shares in the last quarter. Diversified Trust Co raised its position in Amgen by 76.8% during the fourth quarter. Diversified Trust Co now owns 37,695 shares of the medical research company’s stock valued at $10,857,000 after purchasing an additional 16,376 shares in the last quarter. Nicolet Advisory Services LLC raised its position in Amgen by 4.4% during the third quarter. Nicolet Advisory Services LLC now owns 2,805 shares of the medical research company’s stock valued at $745,000 after purchasing an additional 117 shares in the last quarter. Platform Technology Partners raised its position in Amgen by 7.4% during the third quarter. Platform Technology Partners now owns 5,830 shares of the medical research company’s stock valued at $1,567,000 after purchasing an additional 402 shares in the last quarter. Finally, Traynor Capital Management Inc. raised its position in Amgen by 9.5% during the fourth quarter. Traynor Capital Management Inc. now owns 18,941 shares of the medical research company’s stock valued at $5,455,000 after purchasing an additional 1,650 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on AMGN shares. Morgan Stanley lowered their price objective on shares of Amgen from $281.00 to $278.00 and set an “equal weight” rating for the company in a research report on Wednesday, February 7th. Raymond James began coverage on shares of Amgen in a report on Thursday, March 28th. They set a “market perform” rating for the company. Oppenheimer reiterated an “outperform” rating and set a $350.00 price target on shares of Amgen in a report on Thursday, February 1st. UBS Group lowered their price target on shares of Amgen from $314.00 to $284.00 and set a “neutral” rating for the company in a report on Wednesday, April 17th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $329.00 price target on shares of Amgen in a report on Wednesday, April 3rd. Ten research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to MarketBeat.com, Amgen currently has an average rating of “Moderate Buy” and an average target price of $296.95.

Amgen Trading Up 0.2 %

AMGN traded up $0.60 during trading on Friday, reaching $269.98. 2,436,959 shares of the stock traded hands, compared to its average volume of 2,035,139. The company has a quick ratio of 1.13, a current ratio of 1.65 and a debt-to-equity ratio of 10.14. The stock has a market capitalization of $144.81 billion, a PE ratio of 21.62, a P/E/G ratio of 2.60 and a beta of 0.58. The stock’s 50-day moving average is $275.10 and its 200 day moving average is $281.45. Amgen Inc. has a 12 month low of $211.71 and a 12 month high of $329.72.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, February 6th. The medical research company reported $4.71 EPS for the quarter, beating analysts’ consensus estimates of $4.66 by $0.05. The business had revenue of $8.20 billion for the quarter, compared to analysts’ expectations of $8.13 billion. Amgen had a net margin of 23.83% and a return on equity of 154.27%. The business’s quarterly revenue was up 19.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $4.09 earnings per share. Equities analysts anticipate that Amgen Inc. will post 19.43 earnings per share for the current year.

Amgen Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 7th. Stockholders of record on Friday, May 17th will be given a dividend of $2.25 per share. The ex-dividend date of this dividend is Thursday, May 16th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.33%. Amgen’s dividend payout ratio (DPR) is presently 72.06%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.